Influenza vaccination in immunocompromised patients: Efficacy and safety

Immunotherapy

Volumn 6, Issue 2, 2014, Pages 131-139

  Zbinden, Delphine ^a   Manuel, Oriol ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

adjuvant; biological agents; HIV infection; immunogenicity; intradermal; transplantation

Indexed keywords

ANTIGENS, VIRAL; BIOLOGICAL THERAPY; HIV INFECTIONS; HUMANS; IMMUNITY; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; INFLUENZA VACCINES; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; RISK; TRANSPLANTATION; VACCINATION;

EID: 84893848286     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.171     Document Type: Review

References (80)

1. Zhou H, Thompson WW, Viboud CG et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin. Infect. Dis. 54(10), 1427-1436 (2012).
2. Rothberg MB, Haessler SD. Complications of seasonal and pandemic influenza. Crit. Care Med. 38(Suppl. 4), e91-e97 (2010).
3. Lin JC, Nichol KL. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch. Intern. Med. 161(3), 441-446 (2001). (Pubitemid 32116562)
4. Kumar D, Michaels MG, Morris MI et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect. Dis. 10(8), 521-526 (2010).
5. Hayden FG. Prevention and treatment of influenza in immunocompromised patients. Am. J. Med. 102(3A), 55-60; discussion 75-56 (1997).
6. Nicholson KG, Wood JM, Zambon M. Influenza. Lancet 362(9397), 1733-1745 (2003). (Pubitemid 37468326)
7. Neuzil KM, Coffey CS, Mitchel EF Jr, Griffin MR. Cardiopulmonary hospitalizations during influenza season in adults and adolescents with advanced HIV infection. J. Acquir. Immune Defic. Syndr. 34(3), 304-307 (2003). (Pubitemid 37377365)
8. Martinez E, Marcos MA, Hoyo-Ulloa I et al. Influenza A H1N1 in HIV-infected adults. HIV Med. 12(4), 236-245 (2011).
9. Perez CM, Dominguez MI, Ceballos ME et al. Pandemic influenza A (H1N1) in HIV-1-infected patients. Aids 24(18), 2867-2869 (2010).
10. Cordero E, Manuel O. Influenza vaccination in solid-organ transplant recipients. Curr. Opin. Organ Transplant. 17(6), 601-608 (2012).
11. Cordero E, Perez-Romero P, Moreno A et al. Pandemic influenza A (H1N1) virus infection in solid organ transplant recipients: impact of viral and non-viral co-infection. Clin. Micorbiol. Infect. 18(1), 67-73 (2012).
12. Keane WR, Helderman JH, Luby J, Gailiunas P, Hull AR, Kokko JP. Epidemic renal transplant rejection associated with influenza A victoria. Proc. Clin. Dialysis Transplant Forum 8, 232-236 (1978).
13. Billings JL, Hertz MI, Savik K, Wendt CH. Respiratory viruses and chronic rejection in lung transplant recipients. J. Heart Lung Transplant. 21(5), 559-566 (2002). (Pubitemid 34451028)
14. Garantziotis S, Howell DN, McAdams HP, Davis RD, Henshaw NG, Palmer SM. Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome. Chest 119(4), 1277-1280 (2001). (Pubitemid 32679462)
15. Kumar A, Zarychanski R, Pinto R et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 302(17), 1872-1879 (2009).
16. Vilchez RA, McCurry K, Dauber J et al. Influenza virus infection in adult solid organ transplant recipients. Am. J. Transplant. 2(3), 287-291 (2002). (Pubitemid 36330248)
17. Ljungman P. Respiratory virus infections in stem cell transplant patients: the European experience. Biol. Blood Marrow Transplant. 7(Suppl.) S5-S7 (2001).
18. Hassan IA, Chopra R, Swindell R, Mutton KJ. Respiratory viral infections after bone marrow/peripheral stem-cell transplantation: the Christie hospital experience. Bone Marrow Transplant. 32(1), 73-77 (2003). (Pubitemid 36850283)
19. Raboni SM, Stella V, Cruz CR et al. Laboratory diagnosis, epidemiology, and clinical outcomes of pandemic influenza A and community respiratory viral infections in southern Brazil. J. Clin. Microbiol. 49(4), 1287-1293 (2011).
20. Fabbiani M, Di Giambenedetto S, Sali M et al. Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. Vaccine 29(16), 2836-2839 (2011).
21. Candon S, Thervet E, Lebon P et al. Humoral and cellular immune responses after influenza vaccination in kidney transplant recipients. Am. J. Transplant. 9(10), 2346-2354 (2009).
22. Fine AD, Bridges CB, De Guzman AM et al. Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin. Infect. Dis. 32(12), 1784-1791 (2001). (Pubitemid 32532009)
23. Tasker SA, Treanor JJ, Paxton WB, Wallace MR. Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 131(6), 430-433 (1999). (Pubitemid 29444433)
24. Yamanaka H, Teruya K, Tanaka M et al. Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J. Acquir. Immune Defic. Syndr. 39(2), 167-173 (2005). (Pubitemid 40741114)
25. Crum-Cianflone NF, Eberly LE, Duplessis C et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin. Infect. Dis. 52(1), 138-146 (2011).
26. Gunthard HF, Wong JK, Spina CA et al. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J. Infect. Dis. 181(2), 522-531 (2000). (Pubitemid 30131819)
27. Tebas P, Frank I, Lewis M et al. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. Aids 24(14), 2187-2192 (2010).
28. Bickel M, Wieters I, Khaykin P et al. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. Aids 24(9), F31-F35 (2010).
29. Kroon FP, Van Dissel JT, De Jong JC, Zwinderman K, Van Furth R. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 18(26), 3040-3049 (2000). (Pubitemid 30303809)
30. Schuurmans MM, Tini GM, Dalar L, Fretz G, Benden C, Boehler A. Pandemic 2009 H1N1 influenza virus vaccination in lung transplant recipients: coverage, safety and clinical effectiveness in the Zurich cohort. J. Heart Lung Transplant. 30(6), 685-690 (2011).
31. Hurst FP, Lee JJ, Jindal RM, Agodoa LY, Abbott KC. Outcomes associated with influenza vaccination in the first year after kidney transplantation. Clin. J. Am. Soc. Nephrol. 6(5), 1192-1197 (2011).
32. Sanchez-Fructuoso AI, Prats D, Naranjo P et al. Influenza virus immunization effectivity in kidney transplant patients subjected to two different triple-drug therapy immunosuppression protocols: mycophenolate versus azathioprine. Transplantation 69(3), 436-439 (2000). (Pubitemid 30118129)
33. Kimball P, Verbeke S, Tolman D. Influenza vaccination among heart transplant recipients. Transplantation Proc. 33(1-2), 1785-1786 (2001). (Pubitemid 32238064)
34. Blumberg EA, Albano C, Pruett T et al. The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin. Infect. Dis. 22(2), 295-302 (1996). (Pubitemid 26056158)
35. Scharpe J, Evenepoel P, Maes B et al. Influenza vaccination is efficacious and safe in renal transplant recipients. Am. J. Transplant. 8(2), 332-337 (2008).
36. Briggs WA, Rozek RJ, Migdal SD et al. Influenza vaccination in kidney transplant recipients: cellular and humoral immune responses. Ann. Intern. Med. 92(4), 471-477 (1980). (Pubitemid 10156687)
37. Burbach G, Bienzle U, Stark K et al. Influenza vaccination in liver transplant recipients. Transplantation 67(5), 753-755 (1999). (Pubitemid 29161719)
38. Mazzone PJ, Mossad SB, Mawhorter SD, Mehta AC, Schilz RJ, Maurer JR. The humoral immune response to influenza vaccination in lung transplant patients. Eur Respir. J. 18(6), 971-976 (2001). (Pubitemid 34092871)
39. Hayney MS, Welter DL, Francois M, Reynolds AM, Love RB. Influenza vaccine antibody responses in lung transplant recipients. Progress Transplant. 14(4), 346-351 (2004). (Pubitemid 40444189)
40. Cordero E, Aydillo TA, Perez-Ordonez A et al. Deficient long-term response to pandemic vaccine results in an insufficient antibody response to seasonal influenza vaccination in solid organ transplant recipients. Transplantation 93(8), 847-854 (2012).
41. Cordero E, Perez-Ordonez A, Aydillo TA et al. Therapy with m-TOR inhibitors decreases the response to the pandemic influenza A H1N1 vaccine in solid organ transplant recipients. Am. J. Transplant. 11(10), 2205-2213 (2011).
42. Keshtkar-Jahromi M, Argani H, Rahnavardi M et al. Antibody response to influenza immunization in kidney transplant recipients receiving either azathioprine or mycophenolate: a controlled trial. Am. J. Nephrol. 28(4), 654-660 (2008). (Pubitemid 351832453)
43. Siegrist CA, Ambrosioni J, Bel M et al. Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine. Antiviral Ther. 17(5), 893-903 (2012).
44. Orcurto A, Pascual M, Hoschler K, Aubert V, Meylan P, Manuel O. Impact of anti-T-cell therapy in the immunogenicity of seasonal influenza vaccine in kidney transplant recipients. Transplantation 94(6), 630-636 (2012).
45. Kumar D, Blumberg EA, Danziger-Isakov L et al. Influenza vaccination in the organ transplant recipient: review and summary recommendations. Am. J. Transplant. 11(10), 2020-2030 (2011).
46. Birdwell KA, Ikizler MR, Sannella EC et al. Decreased antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study. Am. J. Kidney Dis. 54(1), 112-121 (2009).
47. Engelhard D, Nagler A, Hardan I et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant. 11(1), 1-5 (1993). (Pubitemid 23086839)
48. Machado CM, Cardoso MR, Da Rocha IF, Boas LS, Dulley FL, Pannuti CS, The benefit of influenza vaccination after Bone Marrow Transplant 36(10), 897-900 (2005).
49. Pauksen K, Linde A, Hammarstrom V et al. Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients. Clin. Infect. Dis. 30(2), 342-348 (2000). (Pubitemid 30131544)
50. Issa NC, Marty FM, Gagne LS et al. Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol. Blood Marrow Transplant. 17(3), 434-438 (2011).
51. Gandhi MK, Egner W, Sizer L et al. Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients. Bone Marrow Transplant. 28(8), 775-781 (2001). (Pubitemid 33085571)
52. Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J. Rheumatol. 34(2), 272-279 (2007).
53. Fomin I, Caspi D, Levy V et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann. Rheum. Dis. 65(2), 191-194 (2006). (Pubitemid 43131992)
54. Elkayam O, Bashkin A, Mandelboim M et al. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin. Arthritis Rheum. 39(6), 442-447 (2010).
55. Calmy A, Bel M, Nguyen A et al. Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patients. HIV Med. 13(4), 207-218 (2012).
56. Manuel O, Pascual M, Hoschler K et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin. Infect. Dis. 52(2), 248-256 (2011).
57. Manuel O, Humar A, Chen MH et al. Immunogenicity and safety of an intradermal boosting strategy for vaccination against influenza in lung transplant recipients. Am. J. Transplant. 7(11), 2567-2572 (2007). (Pubitemid 47561624)
58. Stanley SK, Ostrowski MA, Justement JS et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N. Engl. J. Med. 334(19), 1222-1230 (1996).
59. Fowke KR, D'amico R, Chernoff DN et al. Immunologic and virologic evaluation after influenza vaccination of HIV-1-infected patients. Aids 11(8), 1013-1021 (1997). (Pubitemid 27259524)
60. Yerly S, Wunderli W, Wyler CA et al. Influenza immunization of HIV-1-infected patients does not increase HIV-1 viral load. Aids 8(10), 1503-1504 (1994). (Pubitemid 24296813)
61. Schaffer SA, Husain S, Delgado DH, Kavanaugh L, Ross HJ. Impact of adjuvanted H1N1 vaccine on cell-mediated rejection in heart transplant recipients. Am. J. Transplant. 11(12), 2751-2754 (2011).
62. Katerinis I, Hadaya K, Duquesnoy R et al. De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am. J. Transplant. 11(8), 1727-1733 (2011).
63. Baluch A, Humar A, Eurich D et al. Randomized controlled trial of high-dose intradermal versus standard-dose intramuscular influenza vaccine in organ transplant recipients. Am. J. Transplant. 13(4), 1026-1033 (2013).
64. Orlando G, Pariani E, Mazza F et al. Pandemic influenza vaccine in adult HIV-1-infected patients. Aids 24(13), 2142-2143 (2010).
65. Bickel M, Von Hentig N, Wieters I et al. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin. Infect. Dis. 52(1), 122-127 (2011).
66. Durier C, Desaint C, Lucht F et al. Long-term immunogenicity of two doses of 2009 A/H1N1v vaccine with and without AS03(A) adjuvant in HIV-1-infected adults. Aids 27(1), 87-93 (2013).
67. Bickel M, Lassmann C, Wieters I et al. Immune response after a single dose of the 2010/11 trivalent, seasonal influenza vaccine in HIV-1-infected patients and healthy controls. HIV Clin. Trials 14(4), 175-184 (2013).
68. Siegrist CA, Van Delden C, Bel M et al. Higher memory responses in HIV-infected and kidney transplanted patients than in healthy subjects following priming with the pandemic vaccine. PLoS ONE 7(7), e40428 (2012).
69. Greenberg ME, Lai MH, Hartel GF et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N. Engl. J. Med. 361(25), 2405-2413 (2009).
70. Miraglia JL, Abdala E, Hoff PM et al. Immunogenicity and reactogenicity of 2009 influenza A (H1N1) inactivated monovalent non-adjuvanted vaccine in elderly and immunocompromised patients. PLoS ONE 6(11), e27214 (2011).
71. Mohty B, Bel M, Vukicevic M et al. Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients. Haematologica 96(6), 896-904 (2011).
72. Gabay C, Bel M, Combescure C et al. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheumatism 63(6), 1486-1496 (2011).
73. Manuel O, Humar A, Berutto C et al. Low-dose intradermal versus intramuscular trivalent inactivated seasonal influenza vaccine in lung transplant recipients. J. Heart Lung Transplant. 30(6), 679-684 (2011).
74. Morelon E, Pouteil Noble C, Daoud S et al. Immunogenicity and safety of intradermal influenza vaccination in renal transplant patients who were non-responders to conventional influenza vaccination. Vaccine 28(42), 6885-6890 (2010).
75. La Montagne JR, Fauci AS. Intradermal influenza vaccination-can less be more? N. Engl. J. Med. 351(22), 2330-2332 (2004). (Pubitemid 39552751)
76. Grodeland G, Mjaaland S, Roux KH, Fredriksen AB, Bogen B. DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza. J. Immunol. 191(6), 3221-3231 (2013).
77. Margine I, Krammer F, Hai R et al. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J. Virol. 87(19), 1043s6 (2013).
78. Gordon CL, Langan K, Charles PG et al. Pooled human immunoglobulin therapy in critically ill patients with pandemic 2009 influenza A(H1N1) pneumonitis and immunoglobulin G2 subclass (IgG2) deficiency. Clin. Infect. Dis. 52(3), 422-426 (2011).
79. Ye J, Shao H, Perez DR. Passive immune neutralization strategies for prevention and control of influenza A infections. Immunotherapy 4(2), 175-186 (2012).
80. Pulendran B, Oh JZ, Nakaya HI, Ravindran R, Kazmin DA. Immunity to viruses: learning from successful human vaccines. Immunol. Rev. 255(1), 243-255 (2013).